Humanization & Sequence Optimization

Reducing Immunogenicity While Preserving Affinity

Overview

Therapeutic and diagnostic antibody development increasingly relies on engineering strategies that ensure efficacy, safety, and developability. Among these, antibody humanization is a critical step for minimizing immunogenicity of non-human antibodies while maintaining antigen-binding performance.

At InnoTrace, we provide customized antibody humanization and sequence optimization services using a structure-guided, in silico-assisted approach. Our platform combines CDR grafting, back mutation prediction, and post-translational modification (PTM) risk analysis, delivering optimized antibody variants with reduced immunogenicity and preserved binding affinity.